BBNX Stock Summary and Trading Ideas (Beta Bionics | NASDAQ:BBNX)

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

Beta Bionics trades on the NASDAQ stock market under the symbol BBNX.

As of October 16, 2026, BBNX stock price declined to $16.35 with 643,882 million shares trading.

BBNX has a beta of 0.59, meaning it tends to be less sensitive to market movements. BBNX has a correlation of 0.01 to the broad based SPY ETF.

BBNX has a market cap of $882.02 million. This is considered a Small Cap stock.

Last quarter Beta Bionics reported $32 million in Revenue and -$.53 earnings per share. This beat revenue expectation by $498,768 and exceeded earnings estimates by $.03.

The top ETF exchange traded funds that BBNX belongs to (by Net Assets): VTI, IWM, VXF, IWN, TMSL.

BBNX has underperformed the market in the last year with a price return of -20.7% while the SPY ETF gained +16.7%. BBNX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.3% and -13.8%, respectively, while the SPY returned +1.9% and -0.8%, respectively.

BBNX support price is $16.73 and resistance is $17.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BBNX shares will trade within this expected range on the day.